Home > Boards > US Listed > Medical - Drugs > Antares Pharma, Inc. (ATRS)

From the yahoo board

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
mikeslife Member Profile
 
Followed By 1
Posts 344
Boards Moderated 0
Alias Born 11/09/10
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/21/2020 6:29:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/21/2020 6:28:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/21/2020 6:24:52 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 1:19:20 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/11/2020 7:08:02 AM
Antares Pharma Announces Full-Year 2020 Net Revenue Guidance Range of $135 to $155 Million GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Antares Pharma Appoints Edward Tykot Senior Vice President, Corporate Development GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Antares Pharma Social Media Campaign for XYOSTED® Wins MarCom Platinum Award GlobeNewswire Inc. - 12/6/2019 7:00:10 AM
Antares Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire Inc. - 11/27/2019 5:51:22 PM
Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd. GlobeNewswire Inc. - 11/19/2019 7:00:00 AM
Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd. GlobeNewswire Inc. - 11/19/2019 1:00:00 AM
Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference GlobeNewswire Inc. - 11/13/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2019 4:16:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 7:31:28 AM
Antares Pharma Reports Third Quarter 2019 Operating and Financial Results GlobeNewswire Inc. - 11/5/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/4/2019 7:02:13 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/4/2019 7:00:22 AM
Antares Pharma Announces Receipt of Final Payment From Sale of Zomajet™ Needle-Free Delivery System GlobeNewswire Inc. - 10/31/2019 7:00:05 AM
Antares Pharma to Report Third Quarter 2019 Financial and Operating Results GlobeNewswire Inc. - 10/29/2019 7:00:05 AM
Gazit Globe Offer to Acquire All Minority Shareholder Interests in Subsidiary Atrium Has Not Been Approved GlobeNewswire Inc. - 10/25/2019 10:41:10 AM
Antares Pharma Announces Two Poster Presentations at the 2019 Sexual Medicine Society Scientific Annual Meeting GlobeNewswire Inc. - 10/24/2019 7:00:05 AM
Gazit Globe Reaffirms its Commitment and Price GlobeNewswire Inc. - 10/11/2019 2:41:57 PM
Antares Pharma to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/17/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2019 5:01:34 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2019 4:02:45 PM
mikeslife   Sunday, 01/19/20 06:21:35 PM
Re: None
Post # of 4751 
From the yahoo board
SilverFox10 hours ago
FYI: Potential drug Pfizer utilizing Antares Rescue Pen

I came across a ‘potential’ combination drug device rescue pen that Pfizer may be working on in which they have agreed to partner with ATRS per press release dated back on August 6, 2018. Pfizer has not announced it’s developmental drug at this time but a drug being developed by Zealand's Pharma in which it is developing a rescue pen for hypoglycemia and is currently in Phase 3 trials would qualify as a candidate. Zealand’s drug is “Dasiglucagon” and is being developed to offer a stable ready-to-use rescue treatment for severe hypoglycemia.

All type 1 diabetes patients and the most severely affected type 2 patients depend on insulin injections to maintain blood glucose. Consequently, patients must monitor and adjust their blood glucose levels to remain in proper glycemic control, as both high and low blood glucose may affect their health, both in the short and long term.
Severe hypoglycemia is an acute, life-threatening condition resulting from a critical drop in blood glucose levels associated primarily with insulin therapy and is one of the most feared complications of diabetes treatment. The condition of severe hypoglycemia is most frequently seen in people who inject insulin multiple times per day.

Insulin-dependent diabetics, both type 1 and type 2, can have episodes of severe hypoglycemia, resulting in confusion, loss of consciousness and even death.
With six (6) million or more people across the U.S. using insulin, there's a major need for a treatment for hypoglycemia.
While mild hypoglycemia can be treated by eating or drinking something high in carbohydrates, severe acute episodes require intravenous glucose or an injection of glucagon. Glucagon powder, such as in the GlucaGen HypoKit, requires reconstitution and injection with a syringe. Zealand's approach is a ready-to-use "rescue pen" known as HypoPal.

How common is Diabetes?:
Type 2 diabetes is much more common that type 1. According to the 2017 National Diabetes Statistics Report, there are 30.3 million people in the United States with diabetes. That’s close to 1 in 10 people. Among all these people living with diabetes, 90 to 95 percent have type 2 diabetes.. The percentage of people with diabetes increases with age. Less than 10 percent
of the general population has diabetes, but among those 65 and older, the incidence rate reaches a high of 25.2 percent. Only about 0.18 percent of children under the age of 18 had diabetes in 2015. Men and women get diabetes at roughly the same rate, but incidence rates are higher among certain races and ethnicities. American Indians and Alaskan Natives have the highest prevalence of diabetes among both men and women. The black and Hispanic populations have higher rates of diabetes than non-Hispanic whites.
Less

ReplyReplies (2)10

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist